Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
Crossref DOI link: https://doi.org/10.1186/s13059-016-1050-9
Published Online: 2016-09-21
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Geeleher, Paul
Cox, Nancy J.
Huang, R. Stephanie
Funding for this research was provided by:
National Institutes of Health (UO1GM61393)
Text and Data Mining valid from 2016-09-21
Version of Record valid from 2016-09-21
Article History
Received: 29 June 2016
Accepted: 31 August 2016
First Online: 21 September 2016